Neurol. praxi. 2015;16(1):48-50

Pompe disease - case report of the juvenile form

MUDr. Katarína Okáľová, PhD.1, Mgr. Slavomíra Mattošová2, doc. MUDr. Ján Chandoga CSc.2, MUDr. Viera Holecová3
1 Detská fakultná nemocnica s poliklinikou Banská Bystrica
2 Ústav lekárskej biológie, genetiky a klinickej genetiky LF UK a UN Bratislava
3 Fakultná nemocnica s poliklinikou F. D. Roosevelta Banská Bystrica

Pompe disease is a rare inherited disease that is caused by a deficiency of the enzyme alpha-glucosidase, which is located in the lysosomes and isused to break down glycogen. This disease belongs to the group of lysosomal storage diseases. Excessive glycogen accumulates in the lysosomes in every cell of the body, most affected being skeletal and cardiac muscle. Clinical symptoms can vary widely according to the residual enzyme activity, infantile variants are dominated by the involvement of the heart muscle and juvenile and adult variants are dominated by skeletal muscle disease. In laboratory tests, the majority of patients display elevated levels of creatine kinase. Diagnosis of Pompe disease in patients with clinical signs of deficiency requires proof of α-glucosidase. It may be measured in samples of a muscle biopsy, cultured skin fibroblasts and purified lymphocytes. Detection of alpha-glucosidase activity in dried blood spot is a rapid, non-invasive and reliable methodology for determining GAA activity, especially as an initial screening test. In recent years enzyme replacement therapy with a recombinant purified human enzyme has been available. This paper presents a case report of the early detection of juvenile form.

Keywords: Pompe disease, acid alpha-glucosidase, myopathy

Published: January 26, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Okáľová K, Mattošová S, Chandoga J, Holecová V. Pompe disease - case report of the juvenile form. Neurol. praxi. 2015;16(1):48-50.
Download citation

References

  1. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet. Med. 2006; 8(5): 267-288. Go to original source... Go to PubMed...
  2. Malinová V. Glykogenózy II. typu (DSD II, m. Pompe). Současné možnosti diagnostiky a terapie. Klinická kazuistika Neurol. praxi. 2010; 11(5): 331-335.
  3. Okumiya T, Keulemans JLM, Kroos MA, et al. A new diagnostic assay for glycogenstorage disease type II in mixed leukocytes. Mol. Genet. Metab. 2006; 88: 22-28. Go to original source... Go to PubMed...
  4. Špalek P, Hlavatá A. Pompeho choroba - nové trendy v diagnostike a liečbe. Via practica. 2011; 8(5): 225-229.
  5. Winchester B, Bali D, Bodamer OA. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: Report from an international consensus meeting. Mol. Genet. Metab. 2008; 93: 275-281. Go to original source... Go to PubMed...
  6. Zhang H, Kallwass H, Young SP. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid ?-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Gent. Med. 2006; 8(5): 302-306. Go to original source...
  7. Cupler EJ, Berger KI, Leshner RT. AANEM Consensus Committee on Late-onset Pompe disease. Consensus treatment recommendations for late-onset Pompe disease. Musce Nerve 2012; 45(3): 319-333. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.